Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer.
Attempts to develop novel immunotherapeutic mouse models have been hampered by the lack of an adequate in vivo system. This study was performed to establish an immunocompetent mouse model for the testing of immunotherapy concepts. The in vivo system was based on a svngeneic mouse ovarian surface epithelium (MOSE) cancer, physiologically and biologically closely resembling human epithelial ovarian cancer. In addition, a more aggressive variant containing a mutated form of vascular epithelial growth factor was also evaluated. The growth patterns of these ovarian cancer cells in mice were compared to the established, highly aggressive 4T1 breast cancer model. A clinically-relevant tool for the study of different growth patterns in ovarian cancer, with potential significance for the development of novel immunological methods, was successfully developed.
Janát-Amsbury
Margit Maria
MM
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Baylor College of Medicine, Dryden Rd., Suite 1100, Houston, Texas 77030, USA. amsbury@bcm.edu
Yockman
James William
JW
Anderson
Matthew Linley
ML
Kieback
Dirk Günter
DG
Kim
Sung Wan
SW
D000818:Animals; D048708:Cell Growth Processes / Q000235:genetics / Q000502:physiology; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D049452:Green Fluorescent Proteins / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D007121:Immunocompetence; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000235:genetics / Q000276:immunology* / Q000473:pathology*; D017239:Paclitaxel / Q000494:pharmacology; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics
D042461:Vascular Endothelial Growth Factor A; D049452:Green Fluorescent Proteins; D017239:Paclitaxel